Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sosei Initiates PI Trial for Oropharyngeal Candidiasis Treatment SO-1105
March 12, 2012
- Taiyo to Discontinue Marketing Around 50 Products; Started Notifying Customers Last May
March 12, 2012
- Novo Nordisk Applies for Fixed-Dose Insulin Treatment
March 12, 2012
- Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
- Most Admired Pharma Companies in Japan
March 12, 2012
- Asahi Kasei to Acquire ZOLL Medical of the US for US$2.21 Bil.
March 12, 2012
- 5th Annual Marketing Excellence Japan 2012 – Hilton Tokyo, May 15 - 16
March 9, 2012
- 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
- Novartis Voluntarily Recalls 720,000 Diovan Tablets due to Insect Contamination
March 9, 2012
- The Earthquake-Hit Regions Today 3: “Inventory”as an Edge, Changes in Risk Management
March 9, 2012
- Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
- Daiichi Sankyo Says Mr Yoshiwaka to Become Espha President
March 8, 2012
- MTPC Enters into Agreement for Joint Research of New Vaccines with Canadian Company
March 8, 2012
- US FDA Does Not Approve Additional Indication of AML for Eisai’s Dacogen
March 8, 2012
- “Absolutely No Intention” of Moving Headquarters from Osaka: President Teshirogi of Shionogi
March 8, 2012
- The Earthquake-Hit Regions Today 2: “Irregular Visits” Still Continue for MRs Faced With “Fukushima”
March 8, 2012
- MTPC, Daiichi Sankyo Form Strategic Alliance to Jointly Market 2 Diabetes Treatments
March 7, 2012
- Use of Aricept Generics Is Likely to Expand to Nursing Homes: Pharmacist Survey
March 7, 2012
- The Earthquake-Hit Regions Today 1: Difficulties in Securing Pharmacists, Need for Long Sustained Support
March 7, 2012
- Price Reduction Rates for 4 Major Generics Manufacturers at 8.9% to 12.2%: Jiho Survey
March 7, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…